Stay updated with breaking news from Nasdaq anab. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Leerink Partnrs reissued their outperform rating on shares of AnaptysBio (NASDAQ:ANAB – Free Report) in a research report released on Tuesday morning, Zacks.com reports. Leerink Partnrs also issued estimates for AnaptysBio’s Q1 2024 earnings at ($1.41) EPS, Q2 2024 earnings at ($1.44) EPS, Q3 2024 earnings at ($1.45) EPS, Q4 2024 earnings at ($1.42) EPS, […] ....
AnaptysBio, Inc. (NASDAQ:ANAB – Get Free Report) traded up 3.2% on Wednesday . The stock traded as high as $22.37 and last traded at $22.22. 222,281 shares were traded during trading, a decline of 28% from the average session volume of 308,377 shares. The stock had previously closed at $21.53. Wall Street Analyst Weigh In […] ....
AnaptysBio, Inc. (NASDAQ:ANAB – Get Free Report) CEO Daniel Faga sold 3,000 shares of the company’s stock in a transaction on Monday, March 25th. The shares were sold at an average price of $21.42, for a total transaction of $64,260.00. Following the completion of the transaction, the chief executive officer now owns 749,087 shares of […] ....
AnaptysBio, Inc. (NASDAQ:ANAB – Get Free Report) CEO Daniel Faga sold 3,000 shares of the firm’s stock in a transaction that occurred on Monday, March 25th. The stock was sold at an average price of $21.42, for a total transaction of $64,260.00. Following the sale, the chief executive officer now directly owns 749,087 shares of […] ....
AnaptysBio, Inc. (NASDAQ:ANAB – Get Free Report)’s share price gapped up prior to trading on Tuesday . The stock had previously closed at $23.35, but opened at $26.90. AnaptysBio shares last traded at $25.44, with a volume of 60,543 shares changing hands. Analyst Ratings Changes ANAB has been the topic of several research analyst reports. […] ....